The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Sp277
ROLE OF MYOSIN VB AND P-GLYCOPROTEIN IN THE PATHOGENESIS OF GASTROINTESTINAL DISORDERS
Date
May 6, 2023
Explore related products in the following collection:
Understand drug metabolism and disposition is critical to reduce patient morbidity and mortality. Explore the interplay between bacteria and the intestinal microenvironment unveils new knowledge of host-associated microbial communities that play a key role in the control drug metabolism. Review recent studies implicating gut microbes in the control of host drug transporters either directly, as well as through the direct metabolism of drugs or other aspects of drug disposition.
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…